Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. May 24, 2023; 14(5): 198-202
Published online May 24, 2023. doi: 10.5306/wjco.v14.i5.198
Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
Aya Abunada, Zaid Sirhan, Anita Thyagarajan, Ravi P Sahu
Aya Abunada, Department of Pharmacy, Sidra Medicine, Doha 0000, Qatar
Zaid Sirhan, Anita Thyagarajan, Ravi P Sahu, Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, OH 45435, United States
Author contributions: All the authors were involved in writing, editing, and approving the final version of the manuscript.
Supported by the Elsa U. Pardee Foundation Grant, No. 671432 (to Sahu RP); and NIH R21 Grant, No. ES033806 (to Sahu RP).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ravi P Sahu, BSc, MSc, PhD, Assistant Professor, Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, 230 Health Sciences Bldg, 3640 Colonel Glenn Hwy, Dayton, OH 45435, United States. ravi.sahu@wright.edu
Received: January 9, 2023
Peer-review started: January 9, 2023
First decision: January 31, 2023
Revised: February 28, 2023
Accepted: April 21, 2023
Article in press: April 21, 2023
Published online: May 24, 2023
Abstract

The body of evidence investigating human epidermal growth factor receptor-2 (HER2) directed therapy in patients with breast cancer (BC) has been growing within the last decade. Recently, the use of tyrosine kinase inhibitors (TKIs) has been of particular interest in the treatment of human malignancies. This literature commentary is intended to highlight the most recent findings associated with the widely-studied TKI agents and their clinical significance in improving the outcomes of HER2 positive BC.

Keywords: Human epidermal growth factor receptor-2 positive breast cancer, Tyrosine kinase inhibitors, Lapatinib, Pyrotinib, Tucatinib, Trastuzumab

Core Tip: Newly published randomized controlled trials within the past two years have provided compelling evidence on the use of tyrosine kinase inhibitors (TKIs) such as Lapatinib, Pyrotinib, Neratinib, Tucatinib, Ruxolitinib, and Afatinib. Several of these agents were found to offer better outcomes in terms of progression-free survival when combined with other agents. While some TKIs, namely Lapatinib, and Neratinib, are supported with a large amount of data than others, the medical literature still lacks substantial evidence to draw a clinical conclusion that could modify/add to the present recommendations in human epidermal growth factor receptor-2 positive breast cancer treatment guidelines.